NICE Confirms AGNSS Positive Assessment that Eculizumab (Soliris®) is a Very Effective Treatment for aHUS Patients and Produces Substantial Quality-Adjusted Life Year Gains of a Magnitude Rarely Seen for a New Drug

[Business Wire] – Alexion Pharmaceuticals is pleased that the National Institute for Health and Clinical Excellence Evaluation Committee has acknowledged that eculizumab (Soliri more

View todays social media effects on ALXN

View the latest stocks trending across Twitter. Click to view dashboard

See who Alexion is hiring next, click here to view